Table 10

Most common adverse events reported in placebo-controlled double-blind studies

Entacapone Studies10-aTolcapone Studies10-b
Entacapone (n = 406)Placebo (n = 296)Tolcapone 100 mg t.i.d. (n = 296)Tolcapone 200 mg t.i.d. (n = 298)Placebo (n = 298)
% of patients
Dyskinesia27.313.941.951.319.8
Nausea11.16.430.434.917.8
Insomnia4.43.723.624.818.1
Anorexia<2<218.922.812.8
Dystonia2.72.418.622.117.1
Diarrhea8.43.015.518.17.7
Dizziness7.45.413.26.49.7
Urine discoloration12.602.47.40.7
Hallucination3.42.48.410.45.4
Vomiting<2<28.49.73.7

The adverse events occurring ≥5% more frequently in either COMT inhibitor group compared with placebo group are presented.

    • 10-a Orion, 1998.

    • 10-b Roche, 1998.